PSPraveen K. Singh

Praveen K. Singh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Praveen K. Singh has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genetic architecture of yield and adaptive traits in maize under rainfed conditions using diallel analysis

    by M K Danish, S Praveen, S S Ravinder, Kapoor Ankita

    Hybrid development under rainfed environments requires precise identification of superior parental combinations governed by non-additive gene action. The present study was conducted at the Maize Breeding Research Sub-Station (SKUAST-Jammu), Poonch, during the kharif seasons of 2023 and 2024 under rainfed subtropical conditions to evaluate combining ability and cross-direction effects in maize. Eight diverse inbred lines were crossed in a full diallel design, generating 56 F₁ hybrids that were evaluated along with parents in a randomized block design. Analysis of variance (ANOVA) revealed highly significant differences among genotypes for all 14 phenological, morphological, cob and yield-related traits studied. Full diallel analysis following Griffing’s Method I (fixed model) showed significant general combining ability (GCA) and specific combining ability (SCA) effects, with SCA variance exceeding GCA variance for grain yield per plant (Mean square (MS) = 21119.35) and kernels per cob (MS = 88387.18), indicating predominance of non-additive gene action. A total of four parental lines (CML-141, DMR-649, PMS-116 and IB-3012) exhibited significant positive GCA effects for grain yield and major yield components. A total of three cross combinations, namely CML-141 × DMR-649, PMS-116 × CML-150 and IB-3012 × CML-150, expressed significant positive SCA effects for grain yield, while several crosses showed desirable negative SCA effects for flowering and maturity traits, indicating earliness. Reciprocal effects were significant in only a few combinations, suggesting limited maternal influence. The results demonstrate the effectiveness of SCA-based selection for identifying superior hybrids and provide a practical genetic framework for developing high-yielding and adaptable maize hybrids suited to rainfed agro-ecologies of the north-western Himalayan region.

  • Open Access

    An HLA-E-targeted TCR bispecific molecule redirects T cell immunity against Mycobacterium tuberculosis

    by Rachel L. Paterson, Marco P. La Manna, Victoria Arena De Souza, Andrew Walker, Dawn Gibbs-Howe, Rakesh Kulkarni, Joannah R. Fergusson, Nitha Charles Mulakkal, Mauro Monteiro, Wilawan Bunjobpol, et al.

    Peptides presented by HLA-E, a molecule with very limited polymorphism, represent attractive targets for T cell receptor (TCR)-based immunotherapies to circumvent the limitations imposed by the high polymorphism of classical HLA genes in the human population. Here, we describe a TCR-based bispecific molecule that potently and selectively binds HLA-E in complex with a peptide encoded by the inhA gene of Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis in humans. We reveal the biophysical and structural bases underpinning the potency and specificity of this molecule and demonstrate its ability to redirect polyclonal T cells to target HLA-E-expressing cells transduced with mycobacterial inhA as well as primary cells infected with virulent Mtb. Additionally, we demonstrate elimination of Mtb-infected cells and reduction of intracellular Mtb growth. Our study suggests an approach to enhance host T cell immunity against Mtb and provides proof of principle for an innovative TCR-based therapeutic strategy overcoming HLA polymorphism and therefore applicable to a broader patient population.


  • Open Access

    Immune‐Mobilizing Monoclonal T Cell Receptors Mediate Specific and Rapid Elimination of Hepatitis B–Infected Cells

    by Joannah R. Fergusson, Zoë Wallace, Mary M. Connolly, Amanda P. Woon, Richard J. Suckling, Dominic W. Hine, Claire Barber, Wilawan Bunjobpol, Beak‐San Choi, Sara Crespillo, et al.

    Background and Aims: Therapies for chronic hepatitis B virus (HBV) infection are urgently needed because of viral integration, persistence of viral antigen expression, inadequate HBV‐specific immune responses, and treatment regimens that require lifelong adherence to suppress the virus. Immune mobilizing monoclonal T Cell receptors against virus (ImmTAV) molecules represent a therapeutic strategy combining an affinity‐enhanced T Cell receptor with an anti‐CD3 T Cell‐activating moiety. This bispecific fusion protein redirects T cells to specifically lyse infected cells expressing the target virus‐derived peptides presented by human leukocyte antigen (HLA). Approach and Results: ImmTAV molecules specific for HLA‐A*02:01‐restricted epitopes from HBV envelope, polymerase, and core antigens were engineered. The ability of ImmTAV‐Env to activate and redirect polyclonal T cells toward cells containing integrated HBV and cells infected with HBV was assessed using cytokine secretion assays and imaging‐based killing assays. Elimination of infected cells was further quantified using a modified fluorescent hybridization of viral RNA assay. Here, we demonstrate that picomolar concentrations of ImmTAV‐Env can redirect T cells from healthy and HBV‐infected donors toward hepatocellular carcinoma (HCC) cells containing integrated HBV DNA resulting in cytokine release, which could be suppressed by the addition of a corticosteroid in vitro. Importantly, ImmTAV‐Env redirection of T cells induced cytolysis of antigen‐positive HCC cells and cells infected with HBV in vitro, causing a reduction of hepatitis B e antigen and specific loss of cells expressing viral RNA. Conclusions: The ImmTAV platform has the potential to enable the elimination of infected cells by redirecting endogenous non‐HBV‐specific T cells, bypassing exhausted HBV‐specific T cells. This represents a promising therapeutic option in the treatment of chronic hepatitis B, with our lead candidate now entering trials.